This French multicenter randomized trial assessed whether adding low-dose rivaroxaban to dual antiplatelet therapy reduces left ventricular thrombus incidence at one month in anterior STEMI patients. The strategy targets a persistent problem: subclinical LV thrombus soon after anterior MI with silent embolic implications. The results support targeted thromboprophylaxis in this high-risk subgroup without disproportionate bleeding.
This multicenter randomized clinical trial conducted in France determines whether the addition of low-dose rivaroxaban to dual antiplatelet therapy reduces the incidence of left ventricular thrombus at 1 month in patients with anterior ST-segment elevation myocardial infarction.
